AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment.

Journal: Journal of hepatology
PMID:

Abstract

BACKGROUND & AIMS: Direct-acting antivirals (DAAs) have considerably improved chronic hepatitis C (HCV) treatment; however, follow-up after sustained virological response (SVR) typically neglects the risk of liver-related events (LREs). This study introduces and validates the artificial intelligence-safe score (AI-Safe-C score) to assess the risk of LREs in patients without cirrhosis after successful DAA treatment.

Authors

  • Huapeng Lin
    Department of Gastroenterology and Hepatology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Center for Digestive Diseases Research and Clinical Translation of Shanghai Jiao Tong University, Shanghai, China.
  • Terry Cheuk-Fung Yip
    Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
  • Hye Won Lee
    Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
  • Xiangjun Meng
    Department of Hygienic Inspection, School of Public Health, Jilin University 1163 Xinmin Street Changchun 130021 Jilin China songxiuling@jlu.edu.cn li_juan@jlu.edu.cn jinmh@jlu.edu.cn +86 43185619441.
  • Jimmy Che-To Lai
    Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
  • Sang Hoon Ahn
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Wenjing Pang
    Department of Gastroenterology and Hepatology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Center for Digestive Diseases Research and Clinical Translation of Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Gut Microecology and Associated Major Diseases Research, Shanghai, China.
  • Grace Lai-Hung Wong
    Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
  • Lingfeng Zeng
    Department of General Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Vincent Wai-Sun Wong
    Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong. Electronic address: wongv@mect.cuhk.edu.hk.
  • Victor de Lédinghen
    Hepatology Unit, Hôpital Haut-Lévêque, Bordeaux University Hospital, Bordeaux, France; INSERM U1312, Bordeaux University, Bordeaux, France. Electronic address: professeur.deledinghen@gmail.com.
  • Seung Up Kim
    Department of Internal Medicine and Yonsei Liver Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.